[Aimová D, Svobodová L, Kotrbová V, Mrázová B, Hodek P, Hudecek J, Václavíková R, Frei E, Stiborová M (2007) The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos 35: 1926-34.10.1124/dmd.107.016048]Search in Google Scholar
[Arlt VM, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Stiborova M (2006) Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett 234: 220-31.10.1016/j.canlet.2005.03.035]Search in Google Scholar
[Arlt VM, Hewer A, Sorg BL, Schmeiser HH, Phillips DH, Stiborova M (2004) 3-Aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2. Chem Res Toxicol 17: 1092-101.10.1021/tx049912v]Search in Google Scholar
[Arlt VM, Stiborova M, Henderson CJ, Osborne MR, Bieler CA, Frei E, Martinek V, Sopko B, Wolf CR, Schmeiser HH, Phillips DH (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H: quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65: 2644-52.10.1158/0008-5472.CAN-04-3544]Search in Google Scholar
[Arlt VM, Stiborová M, Henderson CJ, Thiemann M, Frei E, Aimová D, Singh R, Gamboa da Costa G, Schmitz OJ, Farmer PB, Wolf CR, Phillips DH (2008) Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29: 656-65.]Search in Google Scholar
[Arlt VM, Stiborova M, Hewer A, Schmeiser HH, Phillips DH (2003) Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH: cytochrome P450 reductase. Cancer Res 63: 2752-61.]Search in Google Scholar
[Baird WM, Hooven LA, Mahadevan B (2005) Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ Mol Mutagen 45: 106-14.10.1002/em.20095]Search in Google Scholar
[Bořek-Dohalská L, Frei E, Stiborová M (2004) DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69: 603-615.10.1135/cccc20040603]Search in Google Scholar
[Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64: 289-95.10.1016/S0006-2952(02)01072-9]Search in Google Scholar
[Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, Wolf CR (2003) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278: 13480-6.10.1074/jbc.M21208720012566435]Search in Google Scholar
[Henderson CJ, Pass GJ, Wolf CR (2006) The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicology letters 162: 111-7.10.1016/j.toxlet.2005.10.01616343823]Search in Google Scholar
[IARC Monogr Eval Carcinog Risk Chem Hum (1983) Polynuclear Aromatic Compounds 32, 211.]Search in Google Scholar
[Kotrbová V, Aimová D, Březinová A, Janouchová K, Poljaková J, Hodek P, Frei E, Stiborová M (2006) Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. Neuro Endocrinol Lett 27(Suppl. 2): 18-20.]Search in Google Scholar
[Kouri RE, Salerno RA, Whitmire CE (1973) Relationships between aryl hydrocarbon hydroxylase inducibility and sensitivity to chemically induced subcutaneous sarcomas in various strains of mice. J Natl Cancer Inst 50: 363-8.10.1093/jnci/50.2.3634702110]Search in Google Scholar
[Phillips DH (1999) Polycyclic aromatic hydrocarbons in the diet. Mutat Res 443: 139-47.10.1016/S1383-5742(99)00016-2]Search in Google Scholar
[Phillips DH (2002) Smoking-related DNA and protein adducts in human tissues Carcinogenesis 23: 1979-2004.10.1093/carcin/23.12.197912507921]Search in Google Scholar
[Poljaková J, Dračínský M, Frei E, Hudeček J Stiborová, M (2006) The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect. Czech. Chem. Commun. 71: 1169-1185.10.1135/cccc20061169]Search in Google Scholar
[Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hraběta J, Stiborová M (2007) DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett 252: 270-9.10.1016/j.canlet.2006.12.03717306925]Search in Google Scholar
[Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudecek J, Phillips DH, Frei E. (2008) Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH: cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 226: 318-27.10.1016/j.taap.2007.09.01717976674]Search in Google Scholar
[Stiborová M, Bieler CA, Wiessler M, Frei E (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62: 675-84.10.1016/S0006-2952(01)00806-1]Search in Google Scholar
[Stiborová M, Bořek-Dohalská L, Aimová D, Kotrbová V, Kukačková K, Janouchová K, Rupertová M, Ryšlavá H, Hudeček J, Frei E (2006a) Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - Similarity between human and rat systems. Gen Physiol Biophys 25: 245-261.]Search in Google Scholar
[Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E (2003a) DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer 107: 885-890.10.1002/ijc.1151114601046]Search in Google Scholar
[Stiborová M, Martínek V, Rýdlová H, Koblas T, Hodek P (2005) Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett 220: 145-154.10.1016/j.canlet.2004.07.03615766589]Search in Google Scholar
[Stiborová M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T, Frei E (2007a) Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer 120: 243-251.10.1002/ijc.2224717066455]Search in Google Scholar
[Stiborová M, Rupertová M, Aimová D, Ryšlavá H, Frei E (2007b) Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 236: 50-60.10.1016/j.tox.2007.03.02617482743]Search in Google Scholar
[Stiborová M, Rupertová M, Schmeiser HH, Frei E (2006b) Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap 150: 13-23.10.5507/bp.2006.00216936898]Search in Google Scholar
[Stiborová M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M, Frei E (2004) The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 64: 8374-8380.10.1158/0008-5472.CAN-04-220215548707]Search in Google Scholar
[Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E (2003b) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16: 38-47.10.1021/tx020081812693029]Search in Google Scholar
[Svobodová M Šístková J, Dračínská H, Hudeček J, Hodek P, Schmeiser HH, Arlt VM, Frei E, Stiborová M (2007) Reductive activation of environmental pollutants 3-nitrobenzanthrone and 2-nitrobenzanthrone. Che. Listy 100: s277-s279.]Search in Google Scholar
[Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, Nebert DW (2004) Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 65: 1225-37.10.1124/mol.65.5.122515102951]Search in Google Scholar
[Uno S, Dalton TP, Dragin N, Curran CP, Derkenne S, Miller ML, Shertzer HG, Gonzalez FJ, Nebert DW (2006) Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 69: 1103-14.10.1124/mol.105.02150116377763]Search in Google Scholar